Abstract:Background Atherosclerosis, a slowly progressing inflammatory disease, is characterized by the presence of monocyte-derived macrophages. Interventions targeting the inflammatory characteristics of atherosclerosis hold promising potential. Although interleukin (IL)-10 is widely acknowledged for its anti-inflammatory effects, systemic administration of IL-10 has limitations due to its short half-life and significant systemic side effects. Purpose We aimed to investigate the effectiveness of an approach designed to overexpress IL-10 in macrophages and subsequently introduce these genetically modified cells into ApoE-/- mice to promote atherosclerosis regression. Methods We engineered RAW264.7 cells to overexpress IL-10 (referred to as IL-10M) using lentivirusvectors. The ApoE-/- mice were divided into two groups based on the timing of the intervention. The early intervention group (n = 45) received intravenous tail injections from the beginning of Western diet (WD) at six weeks old. The late intervention group (n = 45) started receiving injections at 16 weeks old, 2 months after being fed the WD. Both the early and late intervention group stopped receiving injections after 5 months of being fed the WD. Results The IL-10M exhibited robust IL-10 secretion, maintained phagocytic function, improved mitochondrial membrane potentials, reduced superoxide production and showed a tendency toward the M2 phenotype when exposed to inflammatory stimuli. IL-10M can selectively target plaques in ApoE-/- mice, and oil red staining of the entire aorta unequivocally demonstrated that intervention with IL-10M elicited a substantial reduction in plaque area. H&E staining revealed that mice treated with IL-10M in the early intervention group showed a significant reduction in the ratio of plaque area to lumen area. However, the late intervention group did not exhibit statistically significant differences. Notably, mice treated with IL-10M exhibited significantly smaller necrotic cores and reduction in matrix metalloproteinase 9 within the aortic plaques in both the early and late intervention groups. Additionally, the administration of IL-10M showed no obvious side effects. Conclusion We developed an anti-inflammatory protein delivery system based on engineered macrophages that can target atherosclerotic plaques and reduce the plaque area and necrotic core. This approach has a promising safety profile and has the potential to be a therapeutic strategy for the intervention of atherosclerosis.

Reducing the Damage of Ox-LDL/LOX-1 Pathway to Vascular Endothelial Barrier Can Inhibit Atherosclerosis

Endothelial Foxp1 Suppresses Atherosclerosis Via Modulation of Nlrp3 Inflammasome Activation.

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio

The Atheroprotective Role of Lipoxin A4 Prevents Oxldl-Induced Apoptotic Signaling in Macrophages Via JNK Pathway.

Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism

LOX-1 in atherosclerosis: biological functions and pharmacological modifiers

Concentration polarization of oxidative modification of low-density lipoproteins: its effect on oxidative modification of low-density lipoprotein uptake and apoptosis of the endothelial cells.

Simultaneously Blocking ANGPTL3 and CD47 Prevents the Progression of Atherosclerosis Through Regulating Lipid Metabolism, Macrophagic Efferocytosis and Lipid Peroxidation

Effects of Ox‐LDL on Number and Activity of Circulating Endothelial Progenitor Cells

Effects of Ox-LDL on ABCA1 and MCP-1 in vascular endothelial cell

Mannose-Binding Lectin Reduces Oxidized Low-Density Lipoprotein Induced Vascular Endothelial Cells Injury by Inhibiting LOX1-ox-LDL Binding and Modulating Autophagy

OX40-OX40L interaction targets NFATc1 in ApoE-/- mice during atherogenesis

Paeonol Suppresses Oxidized Low-Density Lipoprotein Induced Endothelial Cell Apoptosis Via Activation of LOX-1/p38MAPK/NF-κB Pathway

The effects of ox-LDL in human atherosclerosis may be mediated in part via the toll-like receptor 4 pathway

Concentration polarization of ox-LDL activates autophagy and apoptosis via regulating LOX-1expression

Ox-LDL Plays Dual Effect in Modulating Expression of Inflammatory Molecles Through LOX-1 Pathway in Human Umbilical Vein Endothelial Cells

The protective effects of annexin A1 against oxidized-LDL-induced monocytes adhesion to endothelial cells: implication in atherosclerosis

Autophagic degradation of LOX-1 is involved in the maintenance of vascular integrity injured by oxLDL and protected by Berberine

Oxidized high-density lipoprotein accelerates atherosclerosis progression by inducing the imbalance between treg and teff in LDLR knockout mice.

Anti-Lox-1 Rescues Endothelial Function in Coronary Arterioles in Atherosclerotic Apo-E Knockout Mice

Macrophages overexpressing interleukin-10 target and prevent atherosclerosis: regression of plaque formation and reduction in necrotic core